Skip to main content

Advertisement

SpringerLink
Log in

Heart Failure With a Normal Ejection Fraction: Treatments for a Complex Syndrome?

  • Heart Failure (J Fang, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Heart failure with a normal ejection fraction (HFNEF) now comprises more than 50 % of all patients with heart failure. As the population ages, HFNEF will continue to be a growing public health problem. Recent studies highlight the heterogeneity of this syndrome with regards to underlying pathophysiologic mechanisms. It has been recognized that multiple physiologic domains of cardiovascular function are abnormal in afflicted patients resulting in a reduced reserve capacity, which contributes in an integrated fashion to produce the observed phenotype. Additionally, the realization that differing aspects of this syndrome (eg, exercise limitations, pulmonary edema, and labile blood pressure) likely each have distinct physiologic causes further adds to the complexity. As a result of the heterogeneous nature of the pathophysiologic processes and comorbid illnesses in this population, there is a wide range of clinical outcomes. Accordingly, appreciation of the global nature of HFNEF ideally will better inform optimal design for future diagnostic and therapeutic strategies. Completed clinical trials have not resulted in any evidence-based treatments available for improving survival. Given the disappointing results of these investigations, there has been renewed interest in developing interventions that target underlying comorbidities and peripheral mechanisms. Additionally, nonpharmacologic interventions such as diet and exercise have shown promise in early, small clinical investigations. Finally, methods to more rationally subgroup patients to identify cohorts that could respond to targeted intervention are essential. Recognizing the success achieved in the treatment of systolic heart failure, or heart failure with a reduced ejection fraction (HFREF) by addressing neurohormonal and renal mechanisms, new therapies for HFNEF may be achieved by a similar shift in attention away from the heart.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16(6):e1–e194.

    Article  PubMed  Google Scholar 

  2. Owan TE, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.

    Article  PubMed  CAS  Google Scholar 

  3. Maurer MS, Hummel SL. Heart failure with a preserved ejection fraction what is in a name? J Am Coll Cardiol. 2011;58(3):275–7.

    Article  PubMed  Google Scholar 

  4. Maurer MS. Heart failure with a normal ejection fraction (HFNEF): embracing complexity. J Card Fail. 2009;15(7):561–4.

    Article  PubMed  Google Scholar 

  5. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation. 2003;107(5):656–8.

    Article  PubMed  Google Scholar 

  6. Murad K, DW Kitzman. Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management. Heart Fail Rev. 2011. doi:10.1007/s10741-011-9258-y.

  7. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387–93.

    Article  PubMed  Google Scholar 

  8. Gandhi SK, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344(1):17–22.

    Article  PubMed  CAS  Google Scholar 

  9. Grossman W. Diastolic dysfunction and congestive heart failure. Circulation. 1990;81(2 Suppl):III1–7.

    PubMed  CAS  Google Scholar 

  10. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 1991;325(22):1557–64.

    Article  PubMed  CAS  Google Scholar 

  11. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101(17):2118–21.

    Article  PubMed  CAS  Google Scholar 

  12. Paulus WJ, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Hear J. 2007;28(20):2539–50.

    Article  Google Scholar 

  13. Maurer MS, et al. Diastolic dysfunction: can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol. 2004;44(8):1543–9.

    Article  PubMed  Google Scholar 

  14. Kawaguchi M, et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107(5):714–20.

    Article  PubMed  Google Scholar 

  15. He KL, et al. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55 % versus 40 % to 55 % versus <40 %. Am J Cardiol. 2009;103(6):845–51.

    Article  PubMed  Google Scholar 

  16. Haykowsky MJ, et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58(3):265–74. This paper demonstrates that exercise intolerance in patients with HFNEF as determined by a reduced VO2 is secondary to peripheral more than central factors.

    Article  PubMed  Google Scholar 

  17. Bench T, et al. Heart failure with normal ejection fraction: consideration of mechanisms other than diastolic dysfunction. Curr Heart Fail Rep. 2009;6(1):57–64.

    Article  PubMed  Google Scholar 

  18. Abramov D, et al. Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions. Am J Cardiol. 2008;102(8):1069–72.

    Article  PubMed  Google Scholar 

  19. Maurer MS, et al. The prevalence and impact of anergia (lack of energy) in subjects with heart failure and its associations with actigraphy. J Card Fail. 2009;15(2):145–51.

    Article  PubMed  Google Scholar 

  20. Maurer MS, et al. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;49(9):972–81.

    Article  PubMed  Google Scholar 

  21. Farr MJ, et al. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol. 2008;102(2):203–6.

    Article  PubMed  Google Scholar 

  22. Zile MR, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118(14):1433–41.

    Article  PubMed  Google Scholar 

  23. Klotz S, et al. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension. 2006;47(5):901–11.

    Article  PubMed  CAS  Google Scholar 

  24. Costanzo MR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675–83.

    Article  PubMed  CAS  Google Scholar 

  25. Borlaug BA, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114(20):2138–47.

    Article  PubMed  Google Scholar 

  26. Borlaug BA, et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54(5):410–8.

    Article  PubMed  Google Scholar 

  27. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4(1):23–36.

    Article  PubMed  Google Scholar 

  28. Melenovsky V, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49(2):198–207.

    Article  PubMed  Google Scholar 

  29. Hundley WG, et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol. 2001;38(3):796–802.

    Article  PubMed  CAS  Google Scholar 

  30. Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

    Article  PubMed  CAS  Google Scholar 

  31. Massie BM, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.

    Article  PubMed  CAS  Google Scholar 

  32. Cleland JG, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Hear J. 2006;27(19):2338–45.

    Article  CAS  Google Scholar 

  33. Ahmed A, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397–403.

    Article  PubMed  CAS  Google Scholar 

  34. Flather MD, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Hear J. 2005;26(3):215–25.

    Article  CAS  Google Scholar 

  35. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981–97.

    Google Scholar 

  36. Hunt SA, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235.

    Article  PubMed  Google Scholar 

  37. Sacks FM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3–10.

    Article  PubMed  CAS  Google Scholar 

  38. Hinderliter AL, et al. The DASH diet and insulin sensitivity. Curr Hypertens Rep. 2011;13(1):67–73.

    Article  PubMed  CAS  Google Scholar 

  39. Hummel SL, et al. Recommendation of low-salt diet and short-term outcomes in heart failure with preserved systolic function. Am J Med. 2009;122(11):1029–36. This study demonstrates the importance of sodium restriction in preventing subsequent heart failure hospitalization in patients with HFNEF.

    Article  PubMed  Google Scholar 

  40. Susic D, Frohlich ED. Optimal treatment of hypertension with diastolic heart failure. Heart Fail Clin. 2008;4(1):117–24.

    Article  PubMed  Google Scholar 

  41. Conard MW, et al. The impact of smoking status on the health status of heart failure patients. Congest Heart Fail. 2009;15(2):82–6.

    Article  PubMed  Google Scholar 

  42. Meurrens K, et al. Smoking accelerates the progression of hypertension-induced myocardial hypertrophy to heart failure in spontaneously hypertensive rats. Cardiovasc Res. 2007;76(2):311–22.

    Article  PubMed  CAS  Google Scholar 

  43. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA. 2008;300(4):431–3.

    Article  PubMed  CAS  Google Scholar 

  44. Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis. 2005;47(6):357–66.

    Article  PubMed  CAS  Google Scholar 

  45. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev. 2008;13(3):367–75.

    Article  PubMed  CAS  Google Scholar 

  46. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316(23):1429–35.

    Google Scholar 

  47. Pfeffer MA, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.

    Article  PubMed  CAS  Google Scholar 

  48. Warner Jr JG, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol. 1999;33(6):1567–72.

    Article  PubMed  CAS  Google Scholar 

  49. Satpathy C, et al. Diagnosis and management of diastolic dysfunction and heart failure. Am Fam Physician. 2006;73(5):841–6.

    PubMed  Google Scholar 

  50. Fung JW, et al. Impact of atrial fibrillation in heart failure with normal ejection fraction: a clinical and echocardiographic study. J Card Fail. 2007;13(8):649–55.

    Article  PubMed  Google Scholar 

  51. Bonow RO, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72(4):853–64.

    Article  PubMed  CAS  Google Scholar 

  52. Lipson LC, et al. Long-term hemodynamic assessment of the porcine heterograft in the mitral position. Late development of valvular stenosis. Circulation. 1981;64(2):397–402.

    Article  PubMed  CAS  Google Scholar 

  53. Setaro JF, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66(12):981–6.

    Article  PubMed  CAS  Google Scholar 

  54. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol. 2006;47(1):1–8.

    Article  PubMed  Google Scholar 

  55. Yip GW, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94(5):573–80.

    Article  PubMed  CAS  Google Scholar 

  56. Davis BR, et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118(22):2259–67.

    Article  PubMed  CAS  Google Scholar 

  57. Beckett NS, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.

    Article  PubMed  CAS  Google Scholar 

  58. Little WC. Hypertensive pulmonary oedema is due to diastolic dysfunction. Eur Heart J. 2001;22(21):1961–4.

    Article  PubMed  CAS  Google Scholar 

  59. Lam CS, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115(15):1982–90.

    Article  PubMed  Google Scholar 

  60. Chen CH, et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol. 1998;32(5):1221–7.

    Article  PubMed  CAS  Google Scholar 

  61. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96(3–4):132–43.

    Article  PubMed  CAS  Google Scholar 

  62. Massie BM, Abdalla I. Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role? Prog Cardiovasc Dis. 1998;40(4):357–69.

    Article  PubMed  CAS  Google Scholar 

  63. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–97.

    Article  PubMed  CAS  Google Scholar 

  64. Calhoun DA, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–19.

    Article  PubMed  CAS  Google Scholar 

  65. Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  PubMed  CAS  Google Scholar 

  66. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    Article  PubMed  CAS  Google Scholar 

  67. Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.

    Article  PubMed  CAS  Google Scholar 

  68. Desai AS, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Hear J. 2011;162(6):966–972 e10. The TOPCAT trial is the largest randomized trial of patients with HFPEF treated with aldosterone antagonists.

    Article  CAS  Google Scholar 

  69. Edelmann F, et al. Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Hear Fail. 2010;12(8):874–82.

    Article  CAS  Google Scholar 

  70. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53(11):905–18.

    Article  PubMed  Google Scholar 

  71. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010;55(6):526–37.

    Article  PubMed  Google Scholar 

  72. Mann T, et al. Factors contributing to altered left ventricular diastolic properties during angina pectoris. Circulation. 1979;59(1):14–20.

    Article  PubMed  CAS  Google Scholar 

  73. Bourdillon PD, et al. Increased regional myocardial stiffness of the left ventricle during pacing-induced angina in man. Circulation. 1983;67(2):316–23.

    Article  PubMed  CAS  Google Scholar 

  74. De Keulenaer GW, Brutsaert DL. Diastolic heart failure: a separate disease or selection bias? Prog Cardiovasc Dis. 2007;49(4):275–83.

    Article  PubMed  Google Scholar 

  75. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure: different phenotypes of the same disease? Eur J Heart Fail. 2007;9(2):136–43.

    Article  PubMed  Google Scholar 

  76. He KL, et al. Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovasc Res. 2004;64(1):72–83.

    Article  PubMed  CAS  Google Scholar 

  77. Kramer K, et al. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Hear J. 2000;140(3):451–5.

    Article  CAS  Google Scholar 

  78. Ross Jr J, Braunwald E. Aortic stenosis. Circulation. 1968;38(1 Suppl):61–7.

    PubMed  Google Scholar 

  79. Nakagawa D, et al. Postoperative outcome in aortic stenosis with diastolic heart failure compared to one with depressed systolic function. Int Heart J. 2007;48(1):79–86.

    Article  PubMed  Google Scholar 

  80. Dineen E, Brent BN. Aortic valve stenosis: comparison of patients with to those without chronic congestive heart failure. Am J Cardiol. 1986;57(6):419–22.

    Article  PubMed  CAS  Google Scholar 

  81. Bonow RO, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52(13):e1–e142.

    Article  PubMed  Google Scholar 

  82. Hachicha Z, et al. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation. 2007;115(22):2856–64.

    Article  PubMed  Google Scholar 

  83. Smith CR, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–98.

    Article  PubMed  CAS  Google Scholar 

  84. Spagnuolo M, et al. Natural history of rheumatic aortic regurgitation. Criteria predictive of death, congestive heart failure, and angina in young patients. Circulation. 1971;44(3):368–80.

    Article  PubMed  CAS  Google Scholar 

  85. Rapaport E. Natural-History of Aortic and Mitral-Valve Disease. Am J Cardiol. 1975;35(2):221–7.

    Article  PubMed  CAS  Google Scholar 

  86. Aronow WS, et al. Prognosis of patients with heart failure and unoperated severe aortic valvular regurgitation and relation to ejection fraction. Am J Cardiol. 1994;74(3):286–8.

    Article  PubMed  CAS  Google Scholar 

  87. Dujardin KS, et al. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation. 1999;99(14):1851–7.

    Article  PubMed  CAS  Google Scholar 

  88. Kitzman DW, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. 2010;3(6):659–67.

    Article  PubMed  Google Scholar 

  89. Arena R, et al. Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation. 2007;116(3):329–43.

    Article  PubMed  Google Scholar 

  90. Kitzman DW, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288(17):2144–50.

    Article  PubMed  Google Scholar 

  91. Kaila K, et al. Heart failure with preserved ejection fraction in the elderly: scope of the problem. Heart Fail Rev. 2011. doi:10.1007/s10741-011-9273-z.

  92. Fleg JL, et al. Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000;102(13):1591–7.

    Article  PubMed  CAS  Google Scholar 

  93. Gary RA, et al. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. Heart Lung. 2004;33(4):210–8.

    Article  PubMed  Google Scholar 

  94. Smart N, et al. Exercise training in systolic and diastolic dysfunction: effects on cardiac function, functional capacity, and quality of life. Am Heart J. 2007;153(4):530–6.

    Article  PubMed  Google Scholar 

  95. Cleland JG, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.

    Article  PubMed  CAS  Google Scholar 

  96. Moss AJ, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.

    Article  PubMed  Google Scholar 

  97. De Sutter J, et al. Prevalence of mechanical dyssynchrony in patients with heart failure and preserved left ventricular function (a report from the Belgian Multicenter Registry on dyssynchrony). Am J Cardiol. 2005;96(11):1543–8.

    Article  PubMed  Google Scholar 

  98. Yu CM, et al. Diastolic and systolic asynchrony in patients with diastolic heart failure: a common but ignored condition. J Am Coll Cardiol. 2007;49(1):97–105.

    Article  PubMed  Google Scholar 

  99. Donal E, et al. Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project. Arch Cardiovasc Dis. 2010;103(6–7):404–10.

    Article  PubMed  Google Scholar 

  100. Georgakopoulos D, et al. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail. 2011;17(2):167–78.

    Article  PubMed  Google Scholar 

  101. Lovett EG, Schafer J, Kaufman CL. Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies. Conference proceedings: … Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Eng Med Biol Soc Conf. 2009;2009:4626–30.

    Google Scholar 

  102. Schlaich MP, et al. Renal denervation and hypertension. Am J Hypertens. 2011;24(6):635–42.

    Article  PubMed  Google Scholar 

  103. Sharma M, Frishman WH, Gandhi K. RESPeRATE: nonpharmacological treatment of hypertension. Cardiol Rev. 2011;19(2):47–51.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

Dr. Maurer is supported by a grant from the National Institutes of Health/National Institute on Aging (5K24AG036778-02).

Disclosures

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Clinical Cardiovascular Research Laboratory for the Elderly, Columbia University Medical Center, Allen Hospital of New York Presbyterian Hospital, 5141 Broadway, 3 Field West, Room 037, New York, NY, 10034, USA

    Samuel Bernard MD & Mathew S. Maurer MD

Authors
  1. Samuel Bernard MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathew S. Maurer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mathew S. Maurer MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernard, S., Maurer, M.S. Heart Failure With a Normal Ejection Fraction: Treatments for a Complex Syndrome?. Curr Treat Options Cardio Med 14, 305–318 (2012). https://doi.org/10.1007/s11936-012-0187-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-012-0187-4

Keywords

Search

Navigation